Healthcare Industry News: Incline Therapeutics
News Release - April 26, 2017
John Tucker appointed as Chief Executive Officer of scPharmaceuticalsLEXINGTON, Mass., April 26, 2017 -- (Healthcare Sales & Marketing Network) -- scPharmaceuticals, Inc. a privately held biopharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, announced the appointment of John Tucker as president and chief executive officer, effective immediately. Mr. Tucker was also elected to the board of directors of scPharmaceuticals.
"John has both the strong leadership skills and the business expertise required to successfully position scPharmaceuticals as a leading biopharmaceutical company," said Jack Khattar, scPharmaceuticals board member who led the search committee. "John's experience building commercial ready infrastructures in both private and public companies, as well as developing new markets, will be enormously beneficial to scPharmaceuticals as we advance our lead program and continue the transition from a research and development company to a commercial-stage organization."
"I am very honored and excited to join scPharmaceuticals, a growing biopharmaceutical company. We have a tremendous opportunity to reduce the burden to the patient while meaningfully reducing the cost of care in the management of heart failure and infectious disease through innovative subcutaneous drug delivery," said John Tucker. "scPharmaceuticals' lead investigational drug product – proprietary subcutaneous furosemide, enabled by the patented sc2WearTM Infusor – has been developed to facilitate convenient patient care while reducing overall costs to the healthcare system."
Mr. Tucker has over 25 years of experience in the pharmaceutical industry where he has held various executive positions in major pharmaceutical and biotechnology companies. Prior to joining scPharmaceuticals, Mr. Tucker served as Chief Executive Officer of Alcresta, developer of enzyme-based products for patients with acute and chronic diseases. While at Alcresta he led regulatory and financing strategies resulting in Alcresta's first product approval and product launch. Prior to Alcresta, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company. There, he developed and drove the overall commercial strategy in support of the company's lead product, IONSYS™, resulting in a $390 million purchase of Incline by The Medicines Company. He joined Incline from AMAG Pharmaceuticals, where he was senior vice president, commercial operations, responsible for all sales and marketing activities for the company. Previously, as president, U.S. operations at Basilea Pharmaceuticals, Mr. Tucker developed the strategy and organization for the planned launch of a hospital-focused product and led the company's commercial development team. Prior to Basilea, Mr. Tucker was executive vice president, sales and marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma. Mr. Tucker holds a BA from Plymouth State College and an MBA from New Hampshire College.
About Heart Failure
Today, over 6.5 million Americans suffer from heart failure representing 34% of all Medicare expenditures. By 2030, costs are expected to increase to $53 billion with over 8 million living with the disease.
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing an innovative platform (sc2WearTM Infusor) that may improve patient care and reduce costs to the healthcare system through subcutaneous delivery of IV-equivalent drugs. Our initial products are in heart failure and infectious disease. For further information on how we are transforming the administration of parenteral drugs, go to www.scpharmaceuticals.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.